Cotreatment of JQ1 and a FLT3 inhibitor, FLT3-TKI, significantly reduces the expression of c-MYC, BCL2 and CDK4/6, while synergistically inducing apoptosis of cultured and primary CD34+ human AML blast progenitor cells. Here, CDK4 is linked to acute myeloid leukemia.